FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffry Vaught

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Peter Waldmeier; Donna Bozyczko-Coyne; Michael Williams; Jeffry L Vaught
Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
Diane E Gingrich; Dandu R Reddy; Mohamed A Iqbal; Jasbir Singh; Lisa D Aimone; Thelma S Angeles; Albom Mark; Shi Yang; Mark A Ator; Sheryl L Meyer; Candy Robinson; Bruce Ruggeri; Craig Dionne; Jeffry L Vaught; John Mallamo; Robert L Hudkins
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Bruce Ruggeri; Jasbir Singh; Diane E Gingrich; Thelma S Angeles; Albom Mark; Shi Yang; Hong Chang; Candy Robinson; Kathryn Hunter; Pawel Dobrzanski; Susan Jones-Bolin; Sonya Pritchard; Lisa D Aimone; Andres Klein-Szanto; Jean-Marc Herbert; Francoise Bono; Paul Schaeffer; Pierre Casellas; Bernard Bourie; Roberto Pili; John T Isaacs; Mark A Ator; Robert L Hudkins; Jeffry L Vaught; John Mallamo; Craig Dionne
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffry Vaught (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Peter Waldmeier; Donna Bozyczko-Coyne; Michael Williams; Jeffry L Vaught
Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
Biochemical pharmacology 2006;72(10):1197-206.
2003: Diane E Gingrich; Dandu R Reddy; Mohamed A Iqbal; Jasbir Singh; Lisa D Aimone; Thelma S Angeles; Albom Mark; Shi Yang; Mark A Ator; Sheryl L Meyer; Candy Robinson; Bruce Ruggeri; Craig Dionne; Jeffry L Vaught; John Mallamo; Robert L Hudkins
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Journal of medicinal chemistry 2003;46(25):5375-88.
2003: Bruce Ruggeri; Jasbir Singh; Diane E Gingrich; Thelma S Angeles; Albom Mark; Shi Yang; Hong Chang; Candy Robinson; Kathryn Hunter; Pawel Dobrzanski; Susan Jones-Bolin; Sonya Pritchard; Lisa D Aimone; Andres Klein-Szanto; Jean-Marc Herbert; Francoise Bono; Paul Schaeffer; Pierre Casellas; Bernard Bourie; Roberto Pili; John T Isaacs; Mark A Ator; Robert L Hudkins; Jeffry L Vaught; John Mallamo; Craig Dionne
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Cancer research 2003;63(18):5978-91.
2001: Anna C Maroney; JP Finn; TJ Connors; John T Durkin; Thelma S Angeles; George W Gessner; Zuoshang Xu; Sheryl L Meyer; Mary J Savage; Lloyd A Greene; Richard W Scott; Jeffry L Vaught
Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.
The Journal of biological chemistry 2001;276(27):25302-8.
2001: Donna Bozyczko-Coyne; Teresa M O'Kane; Zhi-Liang Wu; P Dobrzanski; S Murthy; Jeffry L Vaught; Richard W Scott
CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis.
Journal of neurochemistry 2001;77(3):849-63.
2000: Sarah J Harper; Michael Saporito; Louise Hewson; L Young; David Smith; Michael Rigby; P Jackson; Neil R Curtis; Christopher J Swain; Franz Hefti; Jeffry L Vaught; DJ Sirinathsinghji
CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion.
Neuroreport 2000;11(10):2271-6.
1998: Michael Saporito; E R Brown; S Carswell; A M DiCamillo; M S Miller; Chikara Murakata; NT Neff; Jeffry L Vaught; F A Haun
Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis.
Neuroscience 1998;86(2):461-72.
1998: Craig Dionne; Anna Marie Camoratto; Jitesh P Jani; E Emerson; NT Neff; Jeffry L Vaught; Chikara Murakata; D Djakiew; J Lamb; G Steven Bova; D George; John T Isaacs
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1887-98.
1998: MA Glicksman; AY Chiu; Craig Dionne; M Harty; M Kaneko; Chikara Murakata; Ronald W Oppenheim; David Prevette; D R Sengelaub; Jeffry L Vaught; NT Neff
CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo.
Journal of neurobiology 1998;35(4):361-70.
1997: P C Contreras; Jeffry L Vaught; John Gruner; Celia F Brosnan; C Steffler; Joseph C Arezzo; M E Lewis; John A Kessler; Stuart C Apfel
Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice.
Brain research 1997;774(1-2):20-6.
1997: Anna Marie Camoratto; Jitesh P Jani; Thelma S Angeles; Anna C Maroney; C Y Sanders; Chikara Murakata; NT Neff; Jeffry L Vaught; John T Isaacs; Craig Dionne
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
International journal of cancer. Journal international du cancer 1997;72(4):673-9.
1997: M Kaneko; Y Saito; H Saito; T Matsumoto; Y Matsuda; Jeffry L Vaught; Craig Dionne; Thelma S Angeles; MA Glicksman; NT Neff; David Rotella; J C Kauer; John Mallamo; Robert L Hudkins; Chikara Murakata
Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives.
Journal of medicinal chemistry 1997;40(12):1863-9.
1996: Jeffry L Vaught; P C Contreras; MA Glicksman; NT Neff
Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease.
Ciba Foundation symposium 1996;196():18-27; discussion 27-38.
1995: P C Contreras; C Steffler; E Yu; K Callison; D Stong; Jeffry L Vaught
Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice.
The Journal of pharmacology and experimental therapeutics 1995;274(3):1443-9.
1994: Michael Saporito; E R Brown; K C Hartpence; H M Wilcox; E Robbins; Jeffry L Vaught; S Carswell
Systemic dexamethasone administration increases septal Trk autophosphorylation in adult rats via an induction of nerve growth factor.
Molecular pharmacology 1994;45(3):395-401.
1994: Michael Saporito; E R Brown; K C Hartpence; H M Wilcox; Jeffry L Vaught; S Carswell
Chronic 1,25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain.
Brain research 1994;633(1-2):189-96.
1993: M E Lewis; NT Neff; P C Contreras; D B Stong; Ronald W Oppenheim; P E Grebow; Jeffry L Vaught
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
Experimental neurology 1993;124(1):73-88.
1993: Michael Saporito; H M Wilcox; K C Hartpence; M E Lewis; Jeffry L Vaught; S Carswell
Pharmacological induction of nerve growth factor mRNA in adult rat brain.
Experimental neurology 1993;123(2):295-302.
1993: P C Contreras; C Steffler; Jeffry L Vaught
rhIGF-I enhances functional recovery from sciatic crush. Time-course and dose-response study.
Annals of the New York Academy of Sciences 1993;692():314-6.
1993: M E Lewis; Jeffry L Vaught; NT Neff; P E Grebow; K V Callison; E Yu; P C Contreras; F Baldino
The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders.
Annals of the New York Academy of Sciences 1993;692():201-8.